D:II: a.a.\	۸	Г	O A D	D		_	•	ш г о		1.00	17 1 1	Nov 8, 2
Billion)	$\overline{}$	В	C=A-B	D	E=A-D	F	G	H=F-G	I=A-F	J=D-G	K=I-J	
	FY2016	FY2016		FY2015	YoY	Interim	Interim	YoY	2H-FY16	2H-FY2015	YoY	
onsumer Foods	Revised	Initial	Difference						Revised			Reasons for Forecast Revision
	Forecast	Forecast		Results	Change	FY2016	FY2015	Change	Forecast	Results	Change	
sales	817.4	878.6	6 ▲ 61.2	860.9	▲ 43.5	391.6	425.4	▲ 33.8	425.7	435.4	▲ 9.7	
Japan Food Products	403.0	411.8		397.0	5.9	188.9	191.0	▲ 2.1	214.0		8.0 ▲ 0.9 3.2 5.7	【Japan Food Products】
Seasonings & processed foods	195.9	203.8	▲ 7.8	198.2	▲ 2.2	92.8	94.2		103.1		▲ 0.9	Seasonings & processed foods: Downward revision of net sales, mainly due to the in
Frozen foods (Japan)	99.0	99.0	0.0	92.9	6.0	48.7	45.8	2.8	50.3		3.2	from the sale of a subsidiary.
Coffee products	107.9	108.9		105.8	2.0	47.3	50.9	▲ 3.6	60.6		5.7	nom the sale of a substantly.
International Food Products	414.4	466.8		463.9	▲ 49.5	202.7	234.4	▲ 31.6	211.6		<u>▲ 17.8</u>	Frozen foods (Japan): Upward revision of operating income due in part to the positive
Seasonings & processed foods Frozen foods (Oversess)	256.3 94.7	291.7 106.6		280.3 105.5	<u>▲ 23.9</u> <u> </u>	125.5 45.6	142.6 52.0	▲ 17.0 ▲ 6.4	130.8 49.1		▲ 6.9 ▲ 4.3	effect of exchange rates, etc., in addition to sales expansion for Gyoza and The Cha
Frozen foods (Overseas)	94.7	100.0	11.0	105.5	A 10.7	45.6	52.0	▲ 0.4	49.1	33.4	A 4.3	and initiatives with major customers.
Umami seasonings for processed food mfrs. and Sweeteners	63.2	68.3	▲ 5.1	78.0	▲ 14.7	31.5	39.7	▲ 8.1	31.7	38.2	▲ 6.5	
rating income	73.1	76.6		72.5	0.5	34.5	35.0	▲ 0.5	38.5		1.0	[International Food Products]
Japan Food Products	37.0	35.2			6.3	15.2	11.8	3.3	21.7		2.9	Seasonings & processed foods: Downward revisions of both net sales and operating
Seasonings & processed foods			0.1	32.1	2.0	14.5	13.1	1.4		19.0	0.5	income, mainly due to the negative effect of exchange rates, etc.
Frozen foods (Japan)			1.5	4.0	3.0	4.0	1.3	2.6		2.6 2.2 ▲ 5.1	0.5 2.0	
Coffee products	1.10.7	1 10 0	0.2	4.2	2.0	2.0	2.0	▲0.0	1.50	2.2	2.0	Frozen foods (Overseas): Downward revisions of net sales, mainly due to the nega
Shared companywide expenses	▲ 10.7			▲ 9.8	▲ 0.8	▲ 5.3	▲ 4.6	▲ 0.6	▲ 5.3			effect of exchange rates, etc.
ternational Food Products	36.1	41.4		41.9	<u>▲ 5.8</u>	19.2	23.1	<u>▲ 3.9</u>	16.8	18.7	<u>▲ 1.9</u>	
Seasonings & processed foods Frozen foods (Overseas)			▲ 4.1 0.0	2.6	▲ 3.2	1 2	1.0	▲ 3.5		1.5	0.3 ▲0.0	Umami seasonings for processed food mfrs. and Sweeteners: Downward revisions
			0.0	2.0	0.0	1.2	1.0	0.1		1.5	▲0.0	both net sales and operating income, mainly due to the negative effect of exchange
Umami seasonings for processed food mfrs. and Sweeteners			▲ 1.4		▲ 2.4			▲ 0.2			▲ 2.2	etc.
Shared companywide expenses	▲ 14.2	▲ 14.5	0.2	▲ 14.1	▲0.0	▲ 7.3	▲ 6.9	▲ 0.3	▲ 6.9	▲ 7.2	0.2	
ino Science	Revised Forecast	Initial Forecast	Difference	FY2015 Results	Y o Y Change	Interim FY2016	Interim FY2015	Y o Y Change	Revised Forecast	2H-FY2015 Results	Y o Y Change	Reasons for Forecast Revision
sales	216.1								1 1 1 1 1 1 1 1 1 1 1 1 1			
Life Support	210.17		▲ 27.4	232.0	▲ 15 Q	102.0	110.2	A 17 1		112.7	1.2	
	124 5	243.2 145.2		232.0	▲ 15.9	102.0	119.2 74.4	▲ 17.1 ▲ 14.5	114.0	112.7	1.2	
Animai nutrition	124.5 79.4	145.2	2 ▲ 20.7	142.4	▲ 17.9	59.9	74.4	▲ 14.5	114.0 64.5	67.9	1.2 ▲ 3.3 ▲ 1.9	
Animal nutrition Specialty chemicals	124.5 79.4		2 <u>▲ 20.7</u>	142.4 94.9	▲ 17.9 ▲ 15.4	59.9 37.5	74.4 51.0		114.0	67.9 43.8	▲ 1.9	
Specialty chemicals		145.2	20.7	142.4	▲ 17.9 ▲ 15.4 0.5	59.9 37.5 21.6	74.4 51.0 21.5	▲ 14.5 ▲ 13.5 0.0	114.0 64.5	67.9 43.8 21.6	▲ 1.9 0.5	
Specialty chemicals Other	79.4	99.6	20.7	142.4 94.9 43.2 4.1	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0	59.9 37.5 21.6 0.7	74.4 51.0 21.5 1.8	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0	114.0 64.5 41.9	67.9 43.8 21.6 2.3	▲ 1.9 0.5 ▲ 2.0	
Specialty chemicals Other ealthcare		99.6	20.7	142.4 94.9 43.2 4.1 89.5	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0	59.9 37.5 21.6 0.7 42.1	74.4 51.0 21.5 1.8 44.7	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5	114.0 64.5	67.9 43.8 21.6 2.3 44.8	▲ 1.9 0.5	
Specialty chemicals Other	79.4	99.6	20.7	142.4 94.9 43.2 4.1 89.5 73.6	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0	59.9 37.5 21.6 0.7 42.1 32.2	74.4 51.0 21.5 1.8 44.7 36.2	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0	114.0 64.5 41.9	67.9 43.8 21.6 2.3 44.8 37.3	▲ 1.9 0.5 ▲ 2.0	
Specialty chemicals Other calthcare	79.4	99.6	20.7	142.4 94.9 43.2 4.1 89.5	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0	59.9 37.5 21.6 0.7 42.1	74.4 51.0 21.5 1.8 44.7	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0	114.0 64.5 41.9	67.9 43.8 21.6 2.3 44.8	▲ 1.9 0.5 ▲ 2.0	
Specialty chemicals Other ealthcare Amino acids Amino acids for pharmaceuticals and foods	79.4	99.6	20.7	142.4 94.9 43.2 4.1 89.5 73.6	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0	59.9 37.5 21.6 0.7 42.1 32.2	74.4 51.0 21.5 1.8 44.7 36.2 18.5	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9	114.0 64.5 41.9	67.9 43.8 21.6 2.3 44.8 37.3	▲ 1.9 0.5 ▲ 2.0	
Specialty chemicals Other Contain the contained by the	79.4	99.6	20.7	142.4 94.9 43.2 4.1 89.5 73.6	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0	59.9 37.5 21.6 0.7 42.1 32.2	74.4 51.0 21.5 1.8 44.7 36.2	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0	114.0 64.5 41.9	67.9 43.8 21.6 2.3 44.8 37.3	▲ 1.9 0.5 ▲ 2.0	【Life Support】
Specialty chemicals Other ealthcare Amino acids Amino acids for pharmaceuticals and foods Pharmaceutical custom manufacturing	79.4	99.6	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5	59.9 37.5 21.6 0.7 42.1 32.2 17.5	74.4 51.0 21.5 1.8 44.7 36.2 18.5	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9	114.0 64.5 41.9	67.9 43.8 21.6 2.3 44.8 37.3 17.0	▲ 1.9 0.5 ▲ 2.0 4.5 2.0	Animal nutrition: Downward revisions of both net sales and operating income due
Specialty chemicals Other ealthcare Amino acids Amino acids for pharmaceuticals and foods Pharmaceutical custom manufacturing Other	79.4	99.6	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0 38.0	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5	59.9 37.5 21.6 0.7 42.1 32.2	74.4 51.0 21.5 1.8 44.7 36.2 18.5	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9	114.0 64.5 41.9	67.9 43.8 21.6 2.3 44.8 37.3	▲ 1.9 0.5 ▲ 2.0	
Specialty chemicals Other ealthcare	79.4	99.6 98.0 17.5	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0 38.0 15.9	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5 4.0 ▲ 6.7	59.9 37.5 21.6 0.7 42.1 32.2 17.5	74.4 51.0 21.5 1.8 44.7 36.2 18.5 17.5 8.4 11.5 8.3	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9 ▲ 3.1 1.4 ▲ 6.4 ▲ 6.6	114.0 64.5 41.9 49.4	67.9 43.8 21.6 2.3 44.8 37.3 17.0 20.0 7.4 5.9	▲ 1.9 0.5 ▲ 2.0 4.5 2.0 4.5 2.0	Animal nutrition: Downward revisions of both net sales and operating income due to drop in selling prices and the negative effect of exchange rates, etc.
Specialty chemicals Other lealthcare Amino acids	91.6	99.6	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0 38.0	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5	59.9 37.5 21.6 0.7 42.1 32.2 17.5	74.4 51.0 21.5 1.8 44.7 36.2 18.5	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9 ▲ 3.1 1.4 ▲ 6.4 ▲ 6.6	114.0 64.5 41.9	67.9 43.8 21.6 2.3 44.8 37.3 17.0 20.0 7.4 5.9	▲ 1.9 0.5 ▲ 2.0 4.5 2.0 4.5 2.0	Animal nutrition: Downward revisions of both net sales and operating income due to drop in selling prices and the negative effect of exchange rates, etc. [Healthcare]
Specialty chemicals Other lealthcare Amino acids	91.6	99.6 98.0 17.5 11.7	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0 15.9 17.5 11.8	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5 4.0 ▲ 6.7 ▲ 7.3	59.9 37.5 21.6 0.7 42.1 32.2 17.5 14.5 9.9 5.0 1.6	74.4 51.0 21.5 1.8 44.7 36.2 18.5 17.5 8.4 11.5 8.3	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9 ▲ 3.1 1.4 ▲ 6.4 ▲ 6.6	114.0 64.5 41.9 49.4 5.7 2.8	67.9 43.8 21.6 2.3 44.8 37.3 17.0 20.0 7.4 5.9 3.4	▲ 1.9 0.5 ▲ 2.0 4.5 2.0 4.5 2.0	Animal nutrition: Downward revisions of both net sales and operating income due to drop in selling prices and the negative effect of exchange rates, etc. [Healthcare] Amino acids: Downward revision of net sales, mainly due to the negative effect of
Specialty chemicals Other lealthcare Amino acids	91.6	99.6 98.0 17.5 11.7	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0 15.9 17.5 11.8 5.5	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5 4.0 ▲ 6.7 ▲ 7.3 ▲ 5.5	59.9 37.5 21.6 0.7 42.1 32.2 17.5 14.5 9.9 5.0 1.6 ▲ 0.8 4.8	74.4 51.0 21.5 1.8 44.7 36.2 18.5 17.5 8.4 11.5 8.3 5.2	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9 ▲ 3.1 1.4 ▲ 6.4 ▲ 6.6 ▲ 6.6	114.0 64.5 41.9 49.4 5.7 2.8	67.9 43.8 21.6 2.3 44.8 37.3 17.0 20.0 7.4 5.9 3.4 0.2	▲ 1.9 0.5 ▲ 2.0 4.5 2.0 3.0 A 0.2 A 0.6 0.5	Animal nutrition: Downward revisions of both net sales and operating income due to drop in selling prices and the negative effect of exchange rates, etc. [Healthcare]
Specialty chemicals Other Iealthcare Amino acids Amino acids for pharmaceuticals and foods Pharmaceutical custom manufacturing Other Iting income ife Support Animal nutrition Specialty chemicals	91.6	99.6 98.0 17.5 11.7	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0 38.0 15.9 17.5 11.8 5.5 10.3	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5 ▲ 6.7 ▲ 7.3 ▲ 5.5 ▲ 1.0	59.9 37.5 21.6 0.7 42.1 32.2 17.5 14.5 9.9 5.0 1.6 ▲ 0.8 4.8	74.4 51.0 21.5 1.8 44.7 36.2 18.5 17.5 8.4 11.5 8.3 5.2 5.2	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9 ▲ 3.1 1.4 ▲ 6.4 ▲ 6.6 ▲ 6.0 ▲ 0.4	114.0 64.5 41.9 49.4 5.7 2.8	67.9 43.8 21.6 2.3 44.8 37.3 17.0 20.0 7.4 5.9 3.4 0.2 5.0 ▲ 0.1	▲ 1.9 0.5 ▲ 2.0 4.5 2.0 3.0 A 0.2 A 0.6 0.5 A 0.5	Animal nutrition: Downward revisions of both net sales and operating income due to drop in selling prices and the negative effect of exchange rates, etc. [Healthcare] Amino acids: Downward revision of net sales, mainly due to the negative effect of
Specialty chemicals Other Healthcare Amino acids Amino acids for pharmaceuticals and foods Pharmaceutical custom manufacturing Other ating income ife Support Animal nutrition Specialty chemicals Other Shared companywide expenses	79.4 91.6 10.8 4.5 0.0	99.6 98.0 17.5 11.7 6.5	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0 38.0 15.9 17.5 11.8 5.5 10.3 ▲ 0.3	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5 ▲ 6.7 ▲ 7.3 ▲ 5.5 ▲ 1.0 ▲ 1.0	59.9 37.5 21.6 0.7 42.1 32.2 17.5 14.5 9.9 5.0 1.6 ▲ 0.8 4.8 ▲ 0.5	74.4 51.0 21.5 1.8 44.7 36.2 18.5 17.5 8.4 11.5 8.3 5.2 5.2 ▲ 0.1	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9 ▲ 3.1 1.4 ▲ 6.4 ▲ 6.6 ▲ 6.6 ▲ 6.0 ▲ 0.4 ▲ 0.3 0.1	114.0 64.5 41.9 49.4 5.7 2.8 0.8	67.9 43.8 21.6 2.3 44.8 37.3 17.0 20.0 7.4 5.9 3.4 0.2 5.0 ▲ 0.1 ▲ 1.6	3.0 4.5 2.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.0.5 4.0.5 4.0.1 0.4	Animal nutrition: Downward revisions of both net sales and operating income due to drop in selling prices and the negative effect of exchange rates, etc. [Healthcare] Amino acids: Downward revision of net sales, mainly due to the negative effect of
Specialty chemicals Other Healthcare Amino acids Amino acids for pharmaceuticals and foods Pharmaceutical custom manufacturing Other Tating income Life Support Animal nutrition Specialty chemicals Other Shared companywide expenses	79.4 91.6 10.8 4.5 0.0	99.6 98.0 98.0 17.5 11.7 6.5	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0 38.0 15.9 17.5 11.8 5.5 10.3 ▲ 0.3 ▲ 0.3 ▲ 3.6 5.7	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5 ▲ 6.7 ▲ 7.3 ▲ 5.5 ▲ 1.0 ▲ 1.0 0.0	59.9 37.5 21.6 0.7 42.1 32.2 17.5 14.5 9.9 5.0 1.6 ▲ 0.8 4.8 ▲ 0.5 ▲ 1.8	74.4 51.0 21.5 1.8 44.7 36.2 18.5 17.5 8.4 11.5 8.3 5.2 5.2 ▲ 0.1 ▲ 2.0	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9 ▲ 3.1 1.4 ▲ 6.4 ▲ 6.6 ▲ 6.6 ▲ 6.0 ▲ 0.4 ▲ 0.3 0.1	114.0 64.5 41.9 49.4 5.7 2.8 0.8	67.9 43.8 21.6 2.3 44.8 37.3 17.0 20.0 7.4 5.9 3.4 0.2 5.0 ▲ 0.1 ▲ 1.6	▲ 1.9 0.5 ▲ 2.0 4.5 2.0 ▲ 0.2 ▲ 0.6 0.5 ▲ 0.5 ▲ 0.1	Animal nutrition: Downward revisions of both net sales and operating income due to drop in selling prices and the negative effect of exchange rates, etc. [Healthcare] Amino acids: Downward revision of net sales, mainly due to the negative effect of
Specialty chemicals Other Healthcare Amino acids Amino acids for pharmaceuticals and foods Pharmaceutical custom manufacturing Other ating income Life Support Animal nutrition Specialty chemicals Other Shared companywide expenses Healthcare Amino acids Amino acids for	79.4 91.6 10.8 4.5 0.0	99.6 98.0 98.0 17.5 11.7 6.5	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0 38.0 15.9 17.5 11.8 5.5 10.3 ▲ 0.3 ▲ 0.3 ▲ 3.6 5.7	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5 ▲ 6.7 ▲ 7.3 ▲ 5.5 ▲ 1.0 ● 1.0 0.0 0.5	59.9 37.5 21.6 0.7 42.1 32.2 17.5 14.5 9.9 5.0 1.6 ▲ 0.8 4.8 ▲ 0.5 ▲ 1.8 3.3	74.4 51.0 21.5 1.8 44.7 36.2 18.5 17.5 8.4 11.5 8.3 5.2 5.2 ▲ 0.1 ▲ 2.0 3.2	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9 ▲ 3.1 1.4 ▲ 6.4 ▲ 6.6 ▲ 6.6 ▲ 6.0 ▲ 0.4 ▲ 0.3 0.1 0.1	114.0 64.5 41.9 49.4 5.7 2.8 0.8	67.9 43.8 21.6 2.3 44.8 37.3 17.0 20.0 7.4 5.9 3.4 0.2 5.0 ▲ 0.1 ▲ 1.6 2.4	3.0 4.5 2.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.0.5 4.0.5 4.0.1 0.4	Animal nutrition: Downward revisions of both net sales and operating income due to drop in selling prices and the negative effect of exchange rates, etc. [Healthcare] Amino acids: Downward revision of net sales, mainly due to the negative effect of
Specialty chemicals Other Healthcare	79.4 91.6 10.8 4.5 0.0	99.6 98.0 98.0 17.5 11.7 6.5	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0 38.0 15.9 17.5 11.8 5.5 10.3 ▲ 0.3 ▲ 0.3 ▲ 3.6 5.7	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5 ▲ 6.7 ▲ 7.3 ▲ 5.5 ▲ 1.0 ● 1.0 0.0 0.5	59.9 37.5 21.6 0.7 42.1 32.2 17.5 14.5 9.9 5.0 1.6 ▲ 0.8 4.8 ▲ 0.5 ▲ 1.8 3.3	74.4 51.0 21.5 1.8 44.7 36.2 18.5 17.5 8.4 11.5 8.3 5.2 5.2 ▲ 0.1 ▲ 2.0 3.2	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9 ▲ 3.1 1.4 ▲ 6.4 ▲ 6.6 ▲ 6.6 ▲ 6.0 ▲ 0.4 ▲ 0.3 0.1 0.1 0.4	114.0 64.5 41.9 49.4 5.7 2.8 0.8	67.9 43.8 21.6 2.3 44.8 37.3 17.0 20.0 7.4 5.9 3.4 0.2 5.0 ▲ 0.1 ▲ 1.6 2.4	3.0 4.5 2.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.0.5 4.0.5 4.0.1 0.4	Animal nutrition: Downward revisions of both net sales and operating income due to drop in selling prices and the negative effect of exchange rates, etc. [Healthcare] Amino acids: Downward revision of net sales, mainly due to the negative effect of
Specialty chemicals Other Healthcare	79.4 91.6 10.8 4.5 0.0	99.6 98.0 98.0 17.5 11.7 6.5	20.7	142.4 94.9 43.2 4.1 89.5 73.6 36.0 38.0 15.9 17.5 11.8 5.5 10.3 ▲ 0.3 ▲ 0.3 ▲ 3.6 5.7	▲ 17.9 ▲ 15.4 0.5 ▲ 3.0 2.0 ▲ 2.5 ▲ 6.7 ▲ 7.3 ▲ 5.5 ▲ 1.0 ● 1.0 0.0 0.5	59.9 37.5 21.6 0.7 42.1 32.2 17.5 14.5 9.9 5.0 1.6 ▲ 0.8 4.8 ▲ 0.5 ▲ 1.8 3.3	74.4 51.0 21.5 1.8 44.7 36.2 18.5 17.5 8.4 11.5 8.3 5.2 5.2 ▲ 0.1 ▲ 2.0 3.2	▲ 14.5 ▲ 13.5 0.0 ▲ 1.0 ▲ 2.5 ▲ 4.0 ▲ 0.9 ▲ 3.1 1.4 ▲ 6.4 ▲ 6.6 ▲ 6.6 ▲ 6.0 ▲ 0.4 ▲ 0.3 0.1 0.1 0.4	114.0 64.5 41.9 49.4 5.7 2.8 0.8	67.9 43.8 21.6 2.3 44.8 37.3 17.0 20.0 7.4 5.9 3.4 0.2 5.0 ▲ 0.1 ▲ 1.6 2.4	3.0 4.5 2.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 2.0 3.0 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.0.5 4.0.5 4.0.1 0.4	Animal nutrition: Downward revisions of both net sales and operating income due to drop in selling prices and the negative effect of exchange rates, etc. [Healthcare] Amino acids: Downward revision of net sales, mainly due to the negative effect of

Other	FY2016 Revised Forecast	FY2016 Initial Forecast	Difference	FY2015 Results	Y o Y Change	Interim FY2016
Net sales	61.5	64.2	▲ 2.7	91.1	▲ 29.6	28.8
Operating income	▲ 2.4	▲ 3.1	0.7	0.7	▲ 3.1	▲ 0.4
Shared companywide expenses	▲ 3.5	▲ 3.4	▲0.0	▲ 3.5	▲0.0	▲ 1.5

▲ 3.2

▲ 3.2

onsolidated	FY2016 Revised Forecast	FY2016 Initial Forecast	Difference	FY2015 Results	Y o Y Change	Interim FY2016	Interim FY2015	Y o Y Change
et sales	1,095.0	1,186.0	▲ 91.0	1,184.1	▲ 89.1	522.5	589.5	▲ 67.0
perating income	81.5	91.0	▲ 9.5	90.8	▲ 9.3	39.1	47.2	▲ 8.0

▲0.0

▲0.0

▲ 0.5

▲ 2.8

0.5

▲ 0.3

0.0

▲ 0.4

▲ 1.5

▲0.0

▲ 1.2

44.8

0.6

▲ 1.6

Interim

FY2015

0.0 **A** 0.3

YoY

Change

▲ 16.0

2H-FY2015 Results	Y o Y Change		
46.2	▲ 13.5		
0.1	▲ 2.0		
▲ 1.8	▲ 0.1		
	Results 46.2 0.1		

1.6

▲ 0.5

2H-FY16 Revised Forecast	2H-FY2015 Results	Y o Y Change
572.4	594.5	▲ 22.0
42.3	43.6	▲ 1.2

Reasons	for Forecas	t Revision
1 (0000110	ioi i orocao	

Reasons for Forecast Revision

0.5

▲0.0

• Forward-looking statements, such as business performance forecasts, made in these materials are based on management's estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.

Nondisclosure (Italic) Approximation

Shared companywide expenses

Other

Unaudited figures are included in these materials for reference.

[•] Amounts presented in these materials are rounded down.

(Reference) FY2016 Revised Forecast

(¥ Billion)

		=				(* Billion)
Summary of Statements of Income	①FY2016 Revised Forecast (Nov, 2016)	②FY2016 Initial Forecast	③Difference (①-②)	④FY2015 Results	Amount (①-④)	% (①/④)
Japan Food Products	403.0	411.8	▲ 8.8	397.0	5.9	1%
International Food Products	414.4	466.8	▲ 52.4	463.9	▲ 49.5	▲ 10%
Life Support	124.5	145.2	▲ 20.7	142.4	▲ 17.9	▲ 12%
Healthcare	91.6	98.0	▲ 6.4	89.5	2.0	2%
Other	61.5	64.2	▲ 2.7	91.1	▲ 29.6	▲32%
Net sales	1,095.0	1,186.0	▲ 91.0	1,184.1	▲ 89.1	▲ 7%
Japan Food Products	37.0	35.2	1.8	30.6	6.3	20%
International Food Products	36.1	41.4	▲ 5.3	41.9	▲ 5.8	▲ 13%
Life Support	4.5	11.7	▲ 7.2	11.8	▲ 7.3	▲ 61%
Healthcare	6.3	5.8	0.5	5.7	0.5	10%
Other	▲ 2.4	▲ 3.1	0.7	0.7	▲ 3.1	▲ 408%
Operating income	81.5	91.0	▲ 9.5	90.8	▲ 9.3	▲ 10%
Interest income	2.5	2.3	0.2	2.8	▲ 0.3	▲ 12%
Dividend income	1.1	1.0	0.1	1.3	▲ 0.2	▲ 16%
Equity in earnings of non-consolidated subsidiaries and affiliates	2.8	1.5	1.3	1.5	1.2	79%
Interest expense	▲ 2.5	▲ 2.6	0.1	▲ 2.2	▲ 0.2	10%
Other	▲ 1.7	▲ 1.7	0.0	▲ 0.1	▲ 1.5	924%
Non-operating income (expenses)	2.2	0.6	1.6	3.2	▲ 1.0	▲33%
Ordinary income	83.7	91.6	▲ 7.9	94.1	▲ 10.4	▲ 11%
Gain on sale of shares in affiliated companies	2.5	_	2.5	_	2.5	_
Gain on step acquisitions	_	_	_	18.0	▲ 18.0	_
Loss on disposal of fixed assets	▲ 1.1	_	▲ 1.1	▲ 2.7	1.6	▲ 60%
Loss on change in equity	▲ 1.1	_	▲ 1.1	_	▲ 1.1	_
Loss on liquidation of affiliates	_	_	_	▲ 6.9	6.9	_
Other	▲ 5.4	▲ 3.2	▲ 2.2	▲ 2.4	▲ 3.0	134%
Extraordinary losses	▲ 5.1	▲ 3.2	▲ 1.9	6.0	▲ 11.0	▲ 185%
Net income before income taxes	78.6	88.4	▲ 9.8	100.1	▲ 21.5	▲21%
Income taxes	24.4	27.3	▲ 2.9	27.0	▲ 2.6	▲9%
Net income	54.2	61.1	▲ 6.9	73.1	▲ 18.9	▲25%
Profit attributable to noncontrolling interests	9.7	10.1	▲ 0.4	9.6	0.0	0%
Net income attributable to owners of parent	44.5	51.0	▲ 6.5	63.4	▲ 18.9	▲29%

[•] Forward-looking statements, such as business performance forecasts, made in these materials are based on management's estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.

[•] Unaudited figures are included in these materials for reference.

[•] Amounts presented in these materials are rounded down.